title: Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.
abstract: OBJECTIVE
  To improve the results of New therapeutic strategies in hepatocellular carcinoma (HCC). We have conducted a phase II study with pegylated liposomal doxorubicin (PLD), 5-fluorouracil (5FU) and folinic acid (FA).
  
  
  METHODS
  Thirty-one patients with hystologically-confirmed, inoperable HCC, received combination chemotherapy with PLD 25 mg/mq on d 1, 5FU 1200 mg/mq in 48 h continuous infusion, and oral FA 30 mg on d 1 and 2 every 3 wk until disease progression or intolerable toxicity.
  
  
  RESULTS
  The median age was 65 years (range 41-82) and 28 patients were hepatitis C virus seropositive (90%). The majority of patients were Child-Pugh Class B (55%). Two patients showed a partial response (PR), and 16 had stable disease (SD). With a median follow-up of 14 mo, the median time to progression of all evaluable patients was 4 mo (95% CI 1.7-7). Median overall survival was 9 mo (95% CI 3-24 mo). After 1 year, 9 of 18 PR/SD patients were alive. Chemotherapy was well tolerated.
  
  
  CONCLUSIONS
  PLD/FU/FA combination seems capable of achieving durable stabilization of HCC. The manageable toxicity supports a role for combination with other anticancer agents.
authors.affiliation: Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Naples, Italy. giuseppedilorenzoncol@hotmail.com
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Lorenzo
authors.forename: Antonio
authors.initials: A
authors.lastname: Rea
authors.forename: Chiara
authors.initials: C
authors.lastname: Carlomagno
authors.forename: Stefano
authors.initials: S
authors.lastname: Pepe
authors.forename: Giovannella
authors.initials: G
authors.lastname: Palmieri
authors.forename: Roberto
authors.initials: R
authors.lastname: Labianca
authors.forename: Antonio
authors.initials: A
authors.lastname: Chirianni
authors.forename: Alfonso
authors.initials: A
authors.lastname: De Stefano
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Esposito
authors.forename: Sabino
authors.initials: S
authors.lastname: De Placido
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Montesarchio
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014803:Vitamin B Complex / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: C506643:liposomal doxorubicin; D014803:Vitamin B Complex; D011092:Polyethylene Glycols; D004317:Doxorubicin; D002955:Leucovorin; D005472:Fluorouracil